Delivery Order SPE2DR25D3103-SPE2DR26F9S33
Award Date 12/23/25
Potential Completion Date 12/24/25
Potential Value $7.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $8,134.43 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 162 mg/0.9 mL syringes on November 7, 2025, with an ultimate completion date of November 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant medication commonly used to treat...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,888.50 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on December 17, 2025, with an ultimate completion date of December 18, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant medication used...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency valued at $16,717.53 for the supply of ACTEMRA 162 mg/0.9 mL syringes. The contract is a firm fixed-price delivery order with an ultimate completion date of September 25, 2025, and was competitively awarded without set-aside designation. This award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,151.60 for ACTEMRA 162 mg/0.9 mL syringes on December 17, 2025, with an ultimate completion date of December 18, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Actemra 400 mg/20 mL vials. This competitively awarded, firm fixed-price delivery order has a ceiling value of $7,109.81 and an ultimate completion date of July 30, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant...
- The Defense Logistics Agency awarded a delivery order valued at $1,885.82 to AmerisourceBergen Drug Corp for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens. This is a firm fixed price, non-set-aside contract with an ultimate completion date of December 22, 2025. The award was issued on December 19, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Actemra 162 mg/0.9 ml syringes, with a ceiling value of $3,431.82 and a firm fixed price structure. This delivery order, which has an ultimate completion date of November 3, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant medication commonly used...
- The Defense Logistics Agency awarded a $2,877.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on August 5, 2025, with an ultimate completion date of August 6, 2025. This non-set-aside contract represents a pharmaceutical delivery to be performed at the contractor's facility in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory conditions, making this a...
- The Defense Logistics Agency awarded a $13,292.11 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL auto-injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility...
- The Defense Logistics Agency (DLA) awarded a $7,362.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 162 mg/0.9 mL Actemra syringes on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, fulfilled this delivery order under its...